Acepodia Announces FDA Clearance of IND Application for ACE723, a Novel Dual-Payload Antibody-Drug Conjugate
Acepodia has received FDA clearance for its investigational new drug application covering ACE723, a dual-payload antibody-drug conjugate. The clearance allows the company to begin a Phase 1 clinical trial. According to the announcement, ACE723 is the first candidate produced through the firm's AD2C process to reach clinical development. Acepodia, listed in Taiwan, operates from Alameda, California and Taipei.
FDA clearance enables initiation of a Phase 1 clinical trial and advances the first AD2C-generated candidate into clinical development ALAMEDA, Calif. and TAIPEI, Sept. 4, 2026 /PRNewswire/ — Acepodia (6976: TT), a clinical-stage biotechnology company developing next-generation cell therapies and antibody-drug conjugates, today announced that the U.S. Food and Drug Administration (FDA) has cleared the […]